Press Detail

Biotest AG: Biotest AG shareholders accept voluntary public tender offer by CREAT Group

News: Biotest AG / Key word(s): Offer

14.06.2017 / 16:05
The issuer is solely responsible for the content of this announcement.


Biotest AG shareholders accept voluntary public tender offer by CREAT Group

Dreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the voluntary public tender offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the bidding company controlled by CREAT Group, by fulfilling the minimum acceptance condition of 75 percent of Biotest ordinary shares outstanding. This represents a major step in the successful completion of this transaction. The final completion of the transaction is still subject to merger control in Turkey as well as regulatory approvals.

Dr. Bernhard Ehmer, CEO of Biotest AG: "We are pleased that our shareholders have accepted this offer from CREAT Group. We now have a strong partner that will strengthen our Biotest Next Level strategy and support investments in the development of new products and the expansion of our international presence."

According to the German Securities Acquisition and Takeover Act (WpÜG), shareholders of Biotest AG who have not tendered their shares can still accept the offer by tendering their shares during the additional acceptance period, which is expected to begin on 22 June, 2017 and will end on 5 July, 2017 at midnight CET (24:00 CET).

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406

PR contact
Dirk Neumüller
phone: +49-6103-801-269

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

14.06.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this